GlassScriptPhysician profile
Melissa N Schwartz
NPI 1124005046
$4,751.40
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,648 · 2020: $87.18 · 2022: $364 · 2023: $431 · 2024: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,491.89 | 2019-2024 | |
| Intersect Ent, INC. | $188.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $174.03 | 2022-2024 | Nucala |
| Genzyme Corporation | $156.82 | 2023-2024 | |
| Medtronic, INC. | $122.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.19 | 2020-2024 | Takhzyro |
| Csl Behring | $105.79 | 2020-2024 | Haegarda |
| Regeneron Healthcare Solutions, INC. | $104.53 | 2023-2024 | Dupixent, Libtayo |
| Alk-Abello, INC | $98.59 | 2019-2022 | |
| Shire North American Group INC | $43.34 | 2019 | |
| Aerin Medical INC. | $42.29 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $36.96 | 2019 | |
| Merck Sharp & Dohme LLC | $21.64 | 2023 | |
| Kaleo, INC. | $17.89 | 2019 | |
| Greer Laboratories, INC. | $16.23 | 2023 | Oralair |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.